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TITLE: CORRELATION OF DOSE TO BONE MARROW WITH 
HEMATOLOGICAL TOXICITY AND MRI BASED ESTIMATION OF 
CONVERSION OF ACTIVE TO INACTIVE BONE MARROW IN LONG 
COURSE CHEMO- RADIATION FOR LOCALLY ADVANCED RECTAL 
CANCER 
DEPARTMENT: RADIOTHERAPY 
NAME OF THE CANDIDATE: JAYANT J BHARGAV 
DEGREE AND SUBJECT: MD RADIOTHERAPY(BRANCH IX) 
NAME OF THE GUIDE: THOMAS SAMUEL RAM 
Aims : To correlate the dose to bone marrow with the incidence and grade  of  
hematological toxicity and to estimate the extent of inactivation of bone marrow in 
patients with locally advanced rectal cancer undergoing neo adjuvant long course 
chemoradiation. 
Methods and materials: 20 patients with locally advanced rectal cancer were 
enrolled for the study after clearance from the institution review board. All the 
patients received preoperative long course radiotherapy using 3D conformal modality 
to a dose of 50.4Gy.They received concurrent chemotherapy with daily Capecitabine 
(825mg/m2). The entire pelvis was contoured on the simulation CT, the active 
marrow (red) bone marrow was delineated on both the pre radiotherapy as well as the 
post radiotherapy MRI of the pelvis on the T1 weighted images. Baseline and weekly 
blood investigations were recorded during the course of therapy. The dosimetric 
parameters such as V5, V10, V20, V30 and V40 were correlated with the incidence of 
Grade 3 or more hematological toxicity. The pre and post radiotherapy volumes of the 
active marrow and the extent (in percentage volume) of inactivation of bone marrow 
(red to yellow marrow conversion) due to LCCRT  was also documented. The Shapiro 
Wilk/Mann Whitney test was used to correlate the bone marrow dose with toxicities 
and the paired T test was used to test the significance of conversion of active to 
inactive marrow. 
Results: The incidence of grade 3 or more toxicity of hemoglobin correlated with 
V30 and V40 values(p value 0.02 and 0.0095 respectively). The toxicity grades of the 
other blood elements however did not show any correlation with any of the dosimetric 
variables. The median value of the pre radiotherapy active marrow was 346.21cc and 
the median of the post radiotherapy active marrow was 116.44cc.The percentage 
inactivation after therapy had a median value of 57.64% (range 38.98% - 
83.39%)There was also a significant conversion of active to inactive bone marrow as 
detected on the MRI, the correlation of the pre and post neoadjuvant 
chemoradiotherapy marrow volumes was highly significant (p value <0.0001) 
Conclusion: The volume of pelvic bone marrow receiving at least 30Gy or more in 
patients undergoing long course chemoradiotherapy for locally advanced rectal cancer 
has a significant impact on anemia. There was also a significant conversion of active 
to inactive bone marrow as detected on the MRI. The significant myelosuppression 
associated with the use of both chemotherapy and radiotherapy in the management of 
rectal cancer warrants efforts to limit the toxicity to the bone marrow. The use of MRI 
and other functional imaging for visualization and delineation of the bone marrow and 
its use in radiotherapy planning is now providing possibilities to further limit  normal 
tissue toxicity 
Keywords: Locally advanced rectal cancer, neoadjuvant chemoradiotherapy, Long 
course chemoradiotherapy, bone marrow, bone marrow sparing radiotherapy, MRI in 
radiotherapy 
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Introduction 
 
 Colorectal cancer is emerging as a major cancer burden with the increase in 
incidence and mortality, both globally as well as in India (1). Neoadjuvant long course 
chemoradiation therapy and Total Mesorectal Excision (TME) is the current standard 
of care in locally advanced rectal cancer (2).Following surgery, patients receive 
adjuvant chemotherapy based on the findings of the surgical pathology(3).It is well 
known that both radiotherapy and chemotherapy leads to significant 
myelosuppression. With the availability of CT based planning several authors have 
attempted to document the dose to bone marrow and correlate the hematological 
toxicity by studying the dose volume histogram(4) (5). There is not enough literature 
at present evaluating the degree of myelosuppression and the extent of bone marrow 
damage caused by neo adjuvant chemoradiotherapy. This study is undertaken to 
estimate the incidence and degree of hematological toxicity, which could be, attributed 
to chemoradiotherapy and objectively estimate the extent of bone marrow injury. 
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Aims and Objectives 
 
-1. To correlate the dose of radiation received by the bone marrow(volume of the marrow 
receiving a specified dose) and the incidence of grade 3-4 hematological toxicity in 
patients undergoing Long course chemoradiation for locally advanced rectal cancer. 
 
-2. To estimate the extent of inactivation of bone marrow caused following completion of 
long course chemoradiation using an MRI based delineation of the marrow 
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Review of literature 
Epidemiology 
 
Colorectal cancer continues to be a major global burden in terms of the incidence and 
the morbidity. Worldwide, Colorectal cancer is the third most common malignancy 
affecting men and the second most common malignancy affecting women(6).Globally 
cancers of the anorectum constitute more than 40% of the total colorectal cancers 
noted. Though the incidence of rectal cancer in India is much lesser than that in 
developed world, it is on a definite increasing trend. In India, when both genders are 
taken together, it ranks fifth in terms of incidence and sixth in terms of mortality(7).	  
The estimated age standardized incidence rate (ASR) of rectal cancer in India is 7.19 
and 5.08 per 100,000 in males and females respectively (1). 
Of particular importance is the observation that there has been an increased number of 
younger (with a mean age of 40-45 years) patients from West Bengal, the North 
Eastern states as well as from Bangladesh, being diagnosed with colorectal cancer (8) 
(9). 
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Figure 1: Worldwide incidence of colorectal cancers (ASR) 
 
 
Figure 2: Worldwide mortality rates of colorectal cancers (ASR) 
	  5	   	  
 
Figure 3: Ten leading cancers in the Indian population 
 	  
	  
 
Figure 4: Predicted incidence of colorectal cancers in the Indian Population in the year 
2015. 
 
 
 
 
 
 
	  6	   	  
 
 
Risk Factors  
The risk factors associated with rectal cancer can be grouped into two 
categories 
 
1)Non modifiable risk factors 
 
 a)	  Age: More than 90% of colorectal cancer occurs in patients aged 50 or more. The 
likelihood of diagnosis of rectal cancer progressively increases after the age of 40,and 
sharply after the age of 50 (10).However, the number of younger patients being 
diagnosed with colorectal cancer, especially in our country, has steadily been 
increasing (1) 
 
b) History of adenomatous polyps: Neoplastic polyps of the colorectum are precursor 
lesions of colorectal cancer (11).  Most of the sporadic colorectal cancers develop 
from the pre existing villous or tubular adenomas. The development of a malignancy 
from an adenoma has a long latency of about 10 years (12). Detection of and removal 
of the precursor prior to malignant transformation may reduce the risk of invasive 
colorectal cancer (13).  
 
c) History of Inflammatory bowel disease: Ulcerative colitis and Crohn’s disease both 
increase the risk of developing colorectal cancer later in the life (11). This warrants 
the adoption of screening earlier when compared to the general population.  
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d) Family history of Colorectal cancer or adenomatous polyps: There is a high risk 
among first-degree family members of patients diagnosed with colorectal cancer and 
adenomatous polyps. Approximately 20-25% of colorectal cancers are detected among 
the first-degree family members. (14) (15) 
 
d) Predisposition due to genetic syndromes: 5 and 10% of Colorectal malignancies are 
detected in people with genetic syndromes, such as FAP and the syndromes of 
Gardner, Lynch and Turcot. 
 
2) Modifiable risk factors 	  
Modifiable risk factors of colorectal cancers include smoking, physical inactivity, 
obesity, eating processed meat and excessive alcohol (16) (11) 
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Anatomy 
 
There is considerable variation and ambiguity regarding the anatomical 
definition of the rectum due to differing anatomical and surgical landmarks. For 
surgical and oncological considerations the anatomy of the rectum is simplified as 
follows: 
The rectum is divided into three parts. The lower rectum is approximately 3 to 
6cm from the anal verge. The mid rectum is from 5-6 cm to 8-10 cm. The upper 
rectum is from 10 cm to 12-15 cm from the anal verge. 
The location of the tumour is usually specified in terms of the distance from 
the anal verge. Occasionally it may be specified based on the dentate line or the 
anorectal ring. The reference anatomical landmark from which the measurements are 
made, have to be clearly mentioned. Likewise, the method of measurement; per rectal 
examination, colonoscopy, flexible endoscopy has to be mentioned. 
The location of the tumour has considerable implications in the prognosis and 
selection of appropriate therapy. The upper third of the rectum is envisaged by the 
peritoneum anteriorly and laterally. The middle third is lined by the peritoneum on the 
anterior aspect only. The lower third of the rectum, which is in close proximity to 
other pelvic structures, is completely devoid of peritoneal covering. 
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Figure 5: Surgical anatomy of Rectum and Anal canal 
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The majority of the lymphatic drainage of the rectum passes along the superior 
hemorrhoidal artery. The para rectal nodes above the level of the middle rectal-valve 
drain along the superior hemorrhoidal lymphatic chain. The lymphatics below the 
level of the middle rectal valve pass to nodes along the middle hemorrhoidal artery, 
obturator fossa, hypogastric and common iliac arteries. The rectovaginal 
septum,Denonvillier’s fascia and the mesorectum has extensive lymphatic supply. 
 
 
Figure 6: Lymphatic drainage of the rectum 
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Management of rectal cancer 
 
  Suspected	  rectal	  growth	  	  Complete	  history	  and	  physical	  examination	  (including	  DRE	  and	  pelvic	  exam)	  
CBC 
Biochemical profile 
Renal profile 
Liver function test 
CEA 
Imaging 
 
EUS 
MRI abdomen and 
pelvis 
CT abdomen and pelvis 
Chest radiograph 
 
*PET-CT(suspected 
metastasis) 	  
BIOPSY 
Colonoscopy 
Multidisciplinary tumour board 
Staging and appropriate treatment 
	  12	   	  
Work-up  	  
The work up of a patient with a suspected rectal growth includes a history, 
physical examination including a per rectal examination, complete blood cell count, 
liver function tests, renal function test and a baseline CEA.  
Colonoscopy or barium enema to evaluate the large intestine for polyps, 
synchronous growths is often needed.  
Imaging studies include a CT or MRI of the abdomen and pelvis for accurate 
delineation of the tumour as well as to rule out metastasis in other abdominal organs. 
MRI of the pelvis with or without the endorectal coil is considered to be more superior 
in visualization of the tumour extent compared to a CT pelvis (17).A PET-CT  would 
be warranted in some scenarios to help in exclusion of distant metastasis. It is, 
however more useful in cases of a recurrent or a suspected recurrent growth (18).The 
Endocrectal Ultrasound is considered to be the imaging modality of choice for 
accurate T staging of the growth (19). A chest radiograph or a CT thorax is warranted 
to rule out lung metastasis. 
A biopsy of the growth is essential and may be done at the time of the 
colonoscopy/sigmoidoscopy or as a guided procedure using endorectal ultrasound or 
CT to help in localization of the tumour. 
The staging of patients with rectal cancer is carried out based on the TNM staging 
based on the American Joint Committee on Cancer (AJCC)/International Union 
Against Cancer (UICC) staging systems (20).The older Dukes’s classification and the 
Modified Aster Coller classification is seldom used nowadays. 
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Figure 7: AJCC TNM staging (2009) 
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Figure 8: AJCC stage grouping
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Figure 9: Representation of different stages of rectal cancer in terms of depth of 
invasion 
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Prognostic factors affecting outcomes 	  
1) Tumour location	  
Tumors above the anorectum drain to the internal iliac lymph nodes 
and have a propensity to metastasize to the liver via the portal 
drainage; those below it drain into the nodes along the inferior rectal 
and external iliac pathways and may metastasize to the lungs via the 
caval drainage.  
Overall, distal tumours have a worse prognosis than the proximal 
growths(21)(22). 
 
2) Tumour stage	  
Tumour staging based on the AJCC or the UICC systems remains the 
dominant factor in determining prognosis(23).  
 
3) Histopathological factors	  
Histology such as signet ring cell type or melanomas have a poorer 
prognosis(24).Higher grade of the tumour (poorly 
differentiated)tumours  are associated with  poorer 
prognosis.Lymphovascular invasion is also considered to be an 
independent factor and the presence of which indicates poorer 
prognosis(25)(26). 
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4) Tumour fixation	  
Tumours which are fixed tend to have poorer surgical outcomes which 
in turn translates into poorer local control and survival 
outcomes(27)(28) 
 
5) Circumferential involvement	  
Circumferential involvement of the tumours may lead to partial or 
complete luminal obstruction. These tumours are found to have a 
higher incidence of lymph nodal metastasis and portend a poorer 
prognosis. (29)(25)(30) 
 
6) Degree of Tumour regression 	  
The routine use of neo adjuvant therapy for locally advanced rectal 
cancer has led to the development of grading systems based on the 
extent of tumour regression. 
Though different grading systems are used, the most commonly used 
are the Mandard and the Dworak  systems. Higher grades of regression 
after neo adjuvant therapy have a better prognosis (31)(32)(33)(34). 
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Figure 10: Tumour regression grading systems 
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Therapeutic options 
 
Surgery 
 
 Surgery has always been the mainstay of treatment in rectal cancers. Early 
efforts at surgery mainly involved wide local excision of tumours. The surgical 
options included: 
Local Excision 
 
a)Trans anal approach:  
 
This approach offers the least morbidity among surgical options. Mainly employed 
for tumours that are less than 8cm from the anal verge. Tumours that are more 
proximal cannot be approached using this technique. 
 
 
b)Trans-Sphincteric(York Mason) approach: 
 
The entire anal sphincter is divided in the midline. Used for tumours near the 
anorectal region. 
 
 
c) Posterior para sacral (Kraske) approach: 
 
A para sacral longitudinal excision from the just above the anus to the inferior aspect 
of the glueus maximus allows a full thickness excision of proximal growth. 
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A complete resection requires excision of the entire thickness of the growth into the 
fat. The entire growth has to be removed in one uninterrupted specimen, so that the 
pathologist is enabled to give a better description of the margins in relation to the 
tumour. The major limitation of the above mentioned approaches is the fact that 
lymph nodal sampling or excision is not possible. It was noted that that the incidence 
of nodal metastasis in T1 lesions was in the range of 5-10%. But, for T2 it was noted 
to be as high as 20-35% (35).This high rate of lymph nodal metastasis, makes local 
excision unsuitable for T2 lesions. Local excision for even favourable T2 and rarely 
T3 lesions followed by adjuvant therapy has yielded unfavourable results. 
 
At present, local excision is recommended for small growths that are usually less than 
four centimetres, less than 8-10 cm from anal verge, clinically T1 or occasionally, 
favourable T2 lesions. They are usually well to moderately differentiated mobile 
lesions that occupy less than 40% of the circumference. It is also not recommended  
in case of adverse pathological findings like ulceration or lymphovascular invasion 
(36) (37). 
 
Other locally advanced rectal growths necessitate the need for different surgical 
options. 
Historically, excisions with generous 5cm margins both proximally and distally were 
attempted. The intramural spread of tumour was rarely beyond 1.5cm. 2cm proximal 
and distal margins were attempted with acceptable results. Some of the more recent 
studies have indicated that 1cm proximal and distal margins seem to offer equivalent 
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results, while offering the advantage and possibility to proceed with a sphincter 
saving surgery (38) (39). 
Low anterior resection 
 
Low anterior resection (LAR) offers a sphincter sparing surgical excision, while not 
compromising of the local or distant recurrence rates (40). The possibility of saving 
the sphincter reduces with the more distal location of the tumour. 
LAR is now being performed for upper third as well as the middle third and in some 
lower third growths as well (41).  A pre operative assessment of the sphincter tone, 
body habitus and pelvic anatomy is a must for selecting the appropriate patient for the 
procedure. The use of circular stapling devices and the need for modest 1-2cm 
margins has vastly increased the adoption of this approach. 
In patients planned to undergo LAR following neo adjuvant radiotherapy, it is 
advisable to mobilize the splenic flexure so that an unirradiated loop of bowel may be 
later used for the anastomosis. The advantage of the LAR, being the possibility of 
sparing the sphincter, with a resultant better quality of life due to the lack of a 
colostomy, is sometimes compromised by the post operative complications of poor 
sphincter control, bowel urgency and frequency (42).  
 
Abdominoperineal resection 
 
The abdominoperineal resection (APR) has historically been the gold standard for 
distal rectal tumours. It entails a proctectomy with the need for a permanent 
colostomy. 
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The anatomy of the pelvis, the proximity to the prostate or the vagina and the thin 
mesorectum has a considerable bearing of the margins achieved following surgery 
(43). APR in general has more morbidity compared to the LAR. It also suffers from 
the fact that patients report a lower quality of life due to the presence of the 
permanent colostomy (44). 
Worldwide there has been a decrease in the adoption of this approach even for the 
distal tumours (45). 
 
Total Mesorectal excision 
 
Following a standard LAR or APR the local recurrence rates were found to be in the 
range of 15-30%. The high rate of recurrence is probably due to the fact that the 
lateral spread of the tumour spread is not just at the level of the tumour, but all 
through the mesorectum. The standard approaches did not address the same. It was 
noted that local recurrence rates reduced when there was an enbloc removal of the 
tumour along with the endopelvic fascia encompassing it. Total mesorectal excision 
(TME) entails a sharp dissection along the plane to separate the visceral and the 
parietal layers of the endopelvic fascia so that the entire rectal growth along with the 
entire mesorectum is excised out in one uninterrupted gross specimen (46). Surgical 
expertise has a considerable influence on the margins attained and the resultant local 
and distant recurrence rates (47). This approach enables the attainment of a better 
radial margin compared to the other surgical approaches. It is recommended that a 
minimum of 12-15 nodes be excised for complete pathological staging (48). TME, 
although associated with slightly higher rates of complications such as anastomotic 
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leak and delay in wound healing, leads to a higher rate of local control. This has since 
then, become the standard approach in patients undergoing excision. 
TME both open as well as using a laparoscopic approach resulted in similar 
oncological outcomes (49). 
 
 Recent surgical advances employing extra levator APR, laparoscopic 
approaches for TME, ultra low LAR and robotic LAR and TME are in different 
phases of validation. The above approaches all have a common drawback in being 
available only in a few centres worldwide, the adoption of the same in other centres 
has been slow due to the associated cost and long learning curves (47). 
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Adjuvant therapy 
 
 The local failure rates after surgery alone was as high as 25-30% (50).This 
unacceptable rate of local failure necessitates the need for adjuvant therapies to 
provide better local and distal control. 
 
Surgery followed by radiotherapy alone 
  
Post operative radiotherapy requires the use of larger radiation portals in order to 
encompass the perineal scar in patients who have undergone an APR. Regardless of 
the surgical approach, there were concerns of using radiotherapy alone due to the 
larger small bowel volumes and the potentially hypoxic tumour bed leading to 
perceived poorer outcomes.  
Surgery alone versus surgery followed by adjuvant radiotherapy were compared; the 
use of radiotherapy led to a reduced local failure rates, but had no effect on the 
disease free survival or overall survival rates (50) (51). 
Local failure rates after adjuvant radiotherapy alone, though marginally better, were 
still unacceptably high. 
 
Surgery alone versus surgery followed by adjuvant chemotherapy 	  
 Though, as a part of larger trial, the arm that employed post operative 
chemotherapy alone showed a high rate of local failure in the range of 10-15% 
regardless of the regimen used (51). 
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In view of the above results, efforts were made to combine radiotherapy and 
chemotherapy in the adjuvant setting. 
 
Surgery alone versus surgery followed by chemoradiotherapy 
  
As the treatment modality in one of the arms in large trials, adjuvant 
chemoradiotherapy showed increase in the disease free survival as well as overall 
survival (52) (53).Though the use of adjuvant combined chemoradiotherapy led to 
significant improvements in disease free survival and overall survival, there was an 
associated increase in the toxicity compared to the arms using adjuvant chemotherapy 
or radiotherapy alone (52).  
 
Postoperative chemoradiotherapy versus post operative radiotherapy alone 
 
 The post operative chemoradiotherapy arms in different trials all fared better 
in terms of better loco regional control and overall survival (53).There was a 
significant decrease in the rate of distant metastasis in the chemoradiotherapy arm. 
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Neoadjuvant therapy 
 
Neoadjuvant radiotherapy 	  
 The period in which the use of adjuvant therapy was being evaluated also 
witnessed the adoption of neo adjuvant therapy predominantly in Europe. The 
rationale for using neo adjuvant radiotherapy was the fact that radiotherapy could 
provide the possibility of downstaging of tumour leading to better resection with 
adequate margins or to the possibility of providing a sphincter sparing approach. 
 
The usage of pre operative radiotherapy showed better local control and over all 
survival rates. The early trials used a short course of hypofractionated radiotherapy 
followed by surgery after a brief interval. The rates were consistently higher even on a 
longer follow up (54).  
The effect that the interval between the completion of radiotherapy and surgery, had 
on the oncological outcomes was addressed by another trial that showed that a longer 
interval allowed for significant downstaging with a higher pathological response rate 
(55).Pre operative radiotherapy however, led to a higher incidence of complications 
like bowel urgency, incontinence and fecal soiling. 
The drawback of the above trials was the fact that the surgery performed was not the 
optimal surgical approach as in TME. Preoperative radiotherapy followed by TME 
compared to TME showed a lower local relapse in the pre operative radiotherapy arm, 
albeit associated with higher toxicities (56). 
The benefit of pre operative radiotherapy with fewer local recurrences with resultant 
better specific and overall survival was verified by meta analysis (50) 
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 Pre operative chemoradiotherapy versus pre operative radiotherapy 
 
Taking cues from the results of the combined modality arms in the adjuvant setting, 
the same was attempted in the neo adjuvant setting. The trial showed that the 
preoperative usage of chemoradiation resulted in higher pathological complete 
response and lower local relapse rates, but with higher toxicity rates. There was no 
benefit in terms of overall survival (57) (58).  
Overall, preoperative chemoradiotherapy led to fewer local recurrences, higher rates 
of pathological response compared to radiotherapy alone, while having no effect on 
disease specific survival or overall survival. There was an increased incidence of 
grade 3 or more toxicity (59). 
The update of the CAO/ARO/AIO-94  trial after a median follow up of 11 years 
showed the continued benefit of pre operative chemoradiation on local control. There 
was however no improvement in the overall survival (60). The updated results of 
another large trial conducted by the EORTC showed a similar benefit from pre 
operative chemo radiotherapy followed by adjuvant chemotherapy (58) (61).  
Neoadjuvant Long Course chemoradiation (LCCRT) followed by surgery and 
adjuvant chemotherapy is now considered as the standard of care for all locally 
advanced rectal cancers. 
 
Pre operative short course radiotherapy versus the long course neoadjuvant 
chemoradiotherapy 
 
The short course radiotherapy regimen  (20Gy in 5 fractions) is more popular in 
Europe whereas the long course neo adjuvant chemoradiotherapy regimen (50.4 Gy in 
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28 fractions along with 5-FU based chemotherapy) is more popular in the North 
America. The two were compared in a trial, which showed that though there was a 
significantly higher rate of pathological response rate and downstaging in the long 
course regimen, this did not translate into higher rate of sphincter sparing surgery. 
There was also no significant difference in the rates of toxicity, local recurrence or of 
overall survival  (62). There is no clear ‘better’ regimen as yet; reports on long-term 
toxicities are still awaited. 
 
Pre	  operative	  versus	  post	  operative	  therapy	  
 
Some of the early studies showed only a modest increase in disease free survival with 
a trend towards increased overall survival in the pre operative chemoradiotherapy arm 
(63).Some of the later phase III trials showed the benefit of pre operative 
chemoradiotherapy(50.4Gy in 28 fractions with 5-FU based chemotherapy) in 
reducing the number of pelvic recurrences, causing significant downstaging and in 
increasing the number of sphincter sparing surgeries that could be performed. The 
treatment, however had no advantages when it came to disease free survival or overall 
survival. It was also noted that there was also lesser acute toxicity in the pre operative 
arm with better compliance (64) .There was another trial that attempted to evaluate 
pre operative short course radiotherapy(25 Gy in 5 fractions) versus post operative 
chemoradiotherapy. It was found that the pre operative arm had lesser number of local 
failures. There was also an increased disease free survival at 3 years although there 
was no significant increase in the overall survival (65). 
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Choice of chemotherapy 
 
Most of the early trials used 5-FU based chemotherapy along with radiation. The low 
dose continuous infusion of 5-FU was found to be superior to the bolus 5-FU (66). 
The other chemotherapeutic agents used in the neoadjuvant setting are: 
1) Capecitabine 
 
 This is an oral fluoro pyrimidine. It requires the presence of the enzyme 
thymidine phosphorylase to get converted into the active drug (5-FU) within the 
tumour cells. The action of Capecitabine closely mimics that of protracted 5-FU 
infusion. The studies comparing infusional 5-FU versus Capecitabine showed the 
equivalence of the two drugs with respect to disease free and overall survival. The 
toxicity profiles were slightly different in that the patients on Capecitabine 
experienced hand foot skin reactions and proctitis, whereas the patients on infusional 
5-FU had myelosuppression (67). 
 
2) Oxaliplatin 
 
The use of Oxaliplatin in combination with Capecitabine or 5-FU has been 
evaluated. Recent trials have shown that the addition of Oxaliplatin increased the 
incidence of grade 3 or more toxicity, while not improving the oncological outcomes 
(68). The addition of Oxaliplatin to a modified 5-FU regimen resulted in higher rates 
of pathological complete response, the data that looks into the effect of the same on 
disease free survival is still awaited (69). 
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3) Irinotecan 
 
 Various groups have evaluated the combination of Irinotecan along with 
infusional 5-FU or with Capecitabine. Though toxicity rates are slightly high, the 
pathological complete response rate has been in the range of 25-30% (70).The 
translation of the same into improved oncological outcomes is still awaited. 
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Locally advanced rectal cancer 
 
 Locally advanced rectal tumours are those that are 
a) Fixed or adherent to surrounding structures 
b) Of a size that is considered inoperable 
c) Operable but of a size and character that may not yield adequate margins or have a 
high probability of leaving behind micro metastatic disease 
d)Lymph node positivity 
 
 As stated previously pre operative chemoradiotherapy resulted in better local 
control, cancer specific survival and time to treatment failure. It also had a trend 
towards better overall survival, although not significant in statistical terms (71).There 
was an increase in the number of sphincter sparing surgeries that could be performed. 
One of the few disadvantages of the approach is that these patients experienced 
marginally more acute toxicity.  
 
 In cases where the risk of microscopic residual disease is high, even after 
chemoradiotherapy, Intra operative radiotherapy may be utilized in an effort to 
improve the local control. These are still in the experimental phase and require further 
validation of results and toxicity prior to their routine use (72). 	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Radiotherapy in rectal cancer 	  
 Radiotherapy portals are designed to encompass all possible sites of local 
recurrences. Recurrences are mainly noted in the pelvic soft tissue, pelvic nodes, 
anastomotic site or at the perineum (73). Anterior recurrences were mainly noted on 
in T4 tumours .The lymph nodal groups that are routinely included are the internal 
iliac as well as the obturator groups. The external iliac group is included only in case 
of anterior tumour extension or involvement of adjacent structures. 
 
Conventional radiotherapy 	  
Whole pelvic radiotherapy can either be delivered via the commonly used four fields 
(Box technique) or the 3-field approach (Two lateral and a PA field). 
 
Borders are as follows: 
Whole pelvis 
AP/PA fields 
 Superior: Sacral promontory (L5-S1) to encompass the attachment of the 
posterior peritoneum. 
 Lateral: 1.5 beyond the widest bony margins of the true pelvis to encompass 
both the possible lateral extension and the internal iliac chain. 
 Inferior: 3-3.5cm beyond the lower extent of the tumour. The same can be 
located either by direct palpation if it is a lower growth, or with the aid of rectal 
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contrast or an endoscopically placed clip. For post operative cases, in cases of post 
LAR it is placed 3 cm beyond the region of the anastomosis, or in cases of post April 
is placed beyond the anal verge to encompass the perineal scar.  
The inguinal nodes are encompassed only in case of extension into the anal canal or 
involvement of the anterior structures. 
The para aortic nodes are not included in the portals as the involvement of these is 
considered to be metastatic disease. 
 
Lateral fields 
Anterior: For T2 and T3 leisons-After giving generous margins from the 
growth it is generally placed at the posterior margin of the pubic symphysis to 
encompass the internal iliac nodes. 
For T4 lesions: Adequate margins from the growth including its anterior 
extension, it is usually placed at the anterior margin of the pubic symphysis in order 
to encompass the external iliac nodes. 
Posterior: To encompass the entire sacral hollow 
Superior and inferior: Margins same as that of AP/PA fields. 
The boost field is framed to encompass the primary tumour with a 2 cm margin. The 
nodes are not routinely included in the boost field.  
Manual blocks may be placed to shield the small intestine as well as the soft tissue 
posterior to the sacrum. 
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Figure 11: The images on the left are a diagrammatic representation of the portals 
used post LAR; the images on the right are that of the portals used post APR. 
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3D conformal radiotherapy 	  
Conformal therapy offers the possibility of sparing normal tissues, while not 
compromising on the dose delivered to the target volumes. 
The GTV includes both the GTV-T and the GTV-N which is appreciated both 
clinically as well as on imaging. 
The CTV includes the entire mesorectum, presacral space as well as the obturator, 
internal iliac groups. The common iliac and the external iliac are not routinely 
included in all cases. 
The PTV includes a symmetric or asymmetric expansion of the CTV to account for 
organ motion and set up errors. 
The OAR’s are routinely contoured and efforts made to limit to spare them well 
below their threshold limits. 
IMRT,though with its potential to reduce normal tissue dose and its resultant 
advantages, has still not been approved for routine clinical use. Concerns of dose 
heterogeneity as well as the possibility of geographical miss due to variations in the 
position of the target has limited the widespread adoption of IMRT in rectal cancer. 
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Bone marrow 
 
Structure 
 
 The bone marrow is one of the largest organ systems in the body contributing 
to about 5% of the body weight in adults. It is found in the central cavities of long and 
axial bones. It is the major organ for hemopoiesis, also a primary lymphoid organ, 
involved in the production of erythrocytes, granulocytes, monocytes, lymphocytes 
and platelets. It consists of islands of hematopoietic tissue and adipocytes surrounded 
by vascular sinuses, interspersed within the stromal meshwork of trabecular bone.   
The hematopoietic tissue consists of blood cells with their precursors, adipocytes, 
adventitial or barrier cells and macrophages. Hematopoiesis is a compartmentalized 
process. Erythropoiesis takes place in distinct anatomical units referred to as the 
‘erythroblastic islands’; granulopoiesis occurs in distinct islands too, albeit, not as 
organized as the ones involved in erythropoiesis. Megakaryopoiesis, on the other 
hand, occurs adjacent to the sinus endothelium. The hematopoietic cells reach the 
bloodstream after entering into the venous sinuses. The platelets, however, are 
released directly into the blood as cytoplasmic processes of megakaryocytes are in 
direct relation to the sinus lumen.  
Hematopoiesis  though a continuous process can be separated into distinct stages. The 
first stage involves pluripotent stem cells, which are uncommitted stem cells. These 
stem cells maintain their numbers by a process of self-renewal. They also have the 
ability to give rise to all hematopoietic cells of any of the above-mentioned lineages. 
The second stage is when these pluripotent stem cells differentiate into committed 
stem cells. The committed stem cells may either be of the myeloid or the lymphoid 
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series (multipotential stem cells). The third stage is when these committed stem cells 
differentiate into lineage-specific progenitor cells. 
 
Figure 12: Representation of the marrow with the pluripotent stem cell and the 
various lineages 
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Figure 13: Diagrammatic representation of yellow and red marrow; cellular marrow 
and adipocytes. 
 
 Every step in haemopoiesis; production, differentiation and maturation is under the 
regulation of humoral factors. The humoral factors may either be general or be 
specific for particular lineages. They may also be specific for either the early non-
committed cells higher up in the production process or to the more committed lineage 
specific progenitor cells. 
 The distribution of active marrow in human adults is considerably different 
from those in children. About 40% of the marrow is located in the pelvis, 10.9% in 
the lumbar spine, 14.1% in the thoracic spine, 13.1% in the calvaria, 8.3% in the 
upper limb girdle and the remaining in the ribs, cervical spine and the sternum.  
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Figure 14: Distribution of red marrow in adults 
 
Figure 15: Gross visualization of red and yellow marrow 
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Figure 16: Distribution of active marrow in adults with corresponding site-specific 
percentages 
The fact that the cellularity of the bone marrow varies with age is well known. The 
bone marrow of children is more cellular than that in adults. The cellularity is usually 
expressed as the ratio of nucleated hematopoietic cells to fat cells. The ratio is about 
70:30 in young adults, where as in the elderly it usually drops to 30:70. 
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Effect of radiation on bone marrow 
 
 The bone marrow is exquisitely sensitive to radiation. The bone marrow is one 
of the organs that have been exhaustively studies by radiobiologists. The effects of 
radiation on the bone marrow were described soon after the discovery of X rays. The 
mechanisms or bone marrow destruction and the clinical implications of the same 
were described in more detail while investigating the clinicopathological features of 
acute radiation syndromes. The difference in kinetics and turnover of cells of different 
lineages are reflected in the clinical and pathological features that are noticed 
following radiation exposure. The same is also responsible for the differences noted in 
attaining normal state kinetics in the period of recovery. 
The peripheral blood picture of granulocytopenia, thrombocytopenia and anemia 
partly reflect the early effects of the damage caused by radiation. The do not give an 
indication of the extent of damage to the microenvironment, the reserve capacity of 
the marrow or to the damage caused to the stem cells.  
The pluripotent stem cells and blast cells are more radiosensitive than the mature post 
mitotic cells. In both murine as well as in human models the most primitive stem cells 
appear to be responsible for long-term hematopoiesis. The committed stem cells aid in 
engraftment and the initial hematopoietic recovery. Invitro assays or explanted 
stromal cells have been used to study radiation-induced injury to the 
microenvironment.  
 The hematopoietic syndrome that occurs after a whole body exposure of 2.5-
10 Gy is predominantly due to neutropenia and thrombocytopenia. In fractionated 
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doses, however, even large fields upto 20-40 Gy can be tolerated with minimum 
residual effects. This is probably due to the capacity of stem cells from the 
nonirradiated marrow and peripheral blood to seed into the bone that has been 
irradiated. The process of recovery follows a characteristic pattern wherein the 
platelets and granulocytes return to their normal values before the erythrocytes do. 
Complete recovery of hematopoiesis is however seldom possible due to the 
irreversible stromal and microvasculature injury. Reduced production of humoral 
factors may also be a contributory cause.  
 The delayed effects of localized exposure, in addition to the dose, volume of 
marrow irradiated and fractionation, also depends on age. Children appear to have a 
greater capacity for marrow recovery than adults (74). 
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Imaging of the bone marrow 	  
1) Plain radiographs and Computed tomography: Though information about the 
structure of the bone is obtained, visualization of the bone marrow is not possible.  
2) Nuclear medicine imaging: Functional imaging using the above pharmaceuticals, 
along with their appropriate targets, holds great promise in imaging of the functional 
marrow. The common drawback is however, the poor spatial resolution with the 
resultant lack of structural information (75). 
 
Figure 17: Radiopharmaceuticals used in functional imaging of bone marrow 
3) Magnetic resonance imaging: Of the limited radiological options available, MRI is 
the preferred modality for visualization of the marrow. Trabecular bone, water and fat 
all have different MR signals. The relative contributions of the above three along with 
their summated MR signals is responsible for the final MR image. The	  predictable	  rate	  and	  patterns	  of	  red	  to	  yellow	  marrow	  conversion	  and	  their	  corresponding	  characteristic	  features	  of	  the	  MRI	  have	  allowed	  the	  mapping	  of	  the	  bone	  marrow	  varying	   with	   age.	   The	   adult	   red	   and	   yellow	   marrow	   distribution	   is	   generally	  reached	  by	  the	  age	  of	  20	  (76).	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The	   standard	  MR	   imaging	   protocol	   for	   visualization	   of	   the	   bone	  marrow	  may	  include	   coronal	   STIR	   images	   of	   the	   spine,	   pelvis	   and	   sagittal	   T1-­‐w	   and	   fat-­‐suppressed,	  T2-­‐w	  FSE	  or	   STIR	   sagittal	   images	  of	   the	   spine.	  Axial	   and	   contrast-­‐enhanced	  T1-­‐w	  images	  are	  acquired	  in	  when	  appropriate(76)	  
T1-w images:	  	  
• Yellow marrow has a bright signal similar to that of subcutaneous fat 
• Water appears hypo intense  
• The red marrow with 40% water, 40% fat and 20% protein appears darker 
than yellow marrow, with signal intensity slightly more than that of muscle. 
T2-w images:	  
• Yellow marrow appears hypointense 
• Water appears bright 
• The resultant image of the red marrow appears relatively unchanged, appears 
slightly more intense than the muscle. 
• T2w-SPE with selective fat suppression offers a little more distinction 
between the yellow and the red marrow than a conventional T2-w image 
STIR: 
• Short inversion –Time inversion recovery with the advantage of eliminating 
signal from a selective tissue helps in visualization of the pathological area 
against a backdrop of the uninvolved marrow. Coronal STIR images with a 
large field of view helps in volumetric assessment a large area. 
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Contrast enhanced T1-w images: 
• Useful when findings are not discernable on an unenhanced T1-w series. 
• Appropriate when diffuse marrow or meningeal involvement is expected 
	  
Imaging findings post radiotherapy 	  The	  changes	  observed	  post	  radiotherapy	  result	  in	  an	  increased	  T1-­‐w	  signal	  with	  a	  sharp	  demarcation	  corresponding	  to	  the	  radiation	  portal.	  	  The	   sinusoidal	   vasculature	   is	   affected	   post	   radiotherapy;	   the	   hematopoietic	  marrow	   is	   replaced	   by	   the	   fatty	  marrow	  with	   the	   resultant	   hypocellular	   bone	  marrow.	  There	  have	  been	  reports	  that	  at	  doses	  above	  36	  Gy,	  fatty	  replacement	  is	  permanent,	  with	  little	  chance	  of	  hematopoietic	  recovery.	  Below	  30	  Gy,	  however,	  these	  changes	  are	  likely	  to	  be	  reversible	  in	  12–24	  months	  (77)	  (78)	  .	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Figure 18: T1-w images of the pelvis in coronal section (Pre Neoadjuvant 
chemoradiotherapy) Note the hypointense areas representing the areas of red marrow 
(indicated by arrows) 
 
Figure 19: T1-w image of the pelvis in coronal section (Post Neoadjuvant 
chemoradiotherapy); Note the hyperintensity in the sacrum and iliac crests indicating 
the presence of yellow marrow; indicated by arrows.
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Implications of bone marrow depletion  
  
 Approximately 51% of the active marrow is located in the lumbosacral spine 
along with the pelvic girdle. This is of particular interest to the radiation oncologist, 
as radiotherapy for the treatment of lower gastrointestinal, gyneaecological or 
prostatic malignancies involves fields that would encompass the above mentioned 
areas. 
 It is well known that both radiotherapy and chemotherapy have considerable 
effects on the bone marrow in causing myelosuppression. The effects are of an even 
greater significance in cases of radiotherapy along with concurrent chemotherapy, in 
which case there is an additive effect of the individual bone marrow toxicities from 
radiotherapy and chemotherapy. The resultant toxicity noticed during the course or 
following completion of chemoradiotherapy is by no means insignificant. 
 
It may lead to the following: 
 
a) Degrees of hematological toxicity, which would warrant interrupting therapy. 
 
b) Febrile or afebrile neutropenic illnesses with its associated morbidty, risk of 
mortality and their associated cost of management. 
 
c) Need for supportive medications including blood product support 
 
d) Persistent neutropenia leading to discontinuation of further therapy 
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e) Depletion of marrow reserves to an extent, which could compromise future 
adjuvant therapy. 
 
Of considerable concern in the management of lower gastrointestinal and 
gynaecological malignancies is when the use of radiotherapy involving large pelvic 
fields along with concurrent chemotherapy, has the potential to cause significant acute 
and sub acute hematological toxicity. Peripheral blood investigations done during the 
course and following completion of therapy reflect only the acute changes observed. 
It does not, however, estimate the degree of damage caused to the marrow or its 
reserve. Bone marrow biopsies are also unable to characterize the above changes 
fully. Due to the paucity of methods to characterize or visualize the damage to the 
bone marrow, efforts to reduce the dose the bone marrow were seldom made in the 
past. 
 Initial efforts to reduce the dose to the active bone marrow involved using 4 
field box techniques, placing manual shields to spare the ilium and the iliac crests. 
With the advent of conformal and intensity modulated radiotherapy techniques, 
multiple beams were placed along with appropriate shielding offered by customized 
blocks, and multi leaf collimators resulting in significantly reduced doses to the 
organs at risk (OAR’s). Further efforts involved the contouring of the entire pelvis on 
the planning CT and limiting the dose to the OAR’s including the pelvis without 
compromising the dose delivered to the target volumes. “Bone marrow sparing 
IMRT” has been recently attempted both prospectively in the clinic as well as in 
dosimetric studies in the treatment of gynaecological malignancies as well as in anal 
cancers(4)(79)(80)(81)(82)(83). The studies showed significantly lesser doses 
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received by the pelvis. This translated into lesser hematological toxicities, lesser 
number of emergency visits and lesser treatment breaks(84)(85)(86)(87).This 
however resulted in gross over estimation of the amount of active marrow(88)(84).
  
With the developments of novel imaging modalities such as the FLT PET, FDG PET, 
SPECT and the MRI (T1 sequences, DCE) efforts are now being made to contour the 
active marrow alone such that more accurate estimates of the volume and their 
tolerance may be obtained (89)(90). The above methods are however, still in the 
experimental phase and not yet being used in routine clinical practice. 
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Materials and methods 
Study design 
 
Algorithm of study 	  
Recruitment	  of	  participants	  of	  locally	  advanced	  rectal	  cancer	  undergoing	  Long	  course	  chemo	  radiation(based	  on	  inclusion	  and	  exclusion	  criteria	  as	  mentioned)	  	  	  
Baseline	  blood	  investigations	  and	  MRI	  abdomen	  and	  Pelvis	  	  
Contour	  entire	  pelvis	  on	  planning	  CT	  scan	  Contour	  pelvic	  bone	  marrow	  on	  T1	  MRI	  images	  	  
Long	  course	  chemoradiation:3D	  conformal	  Radiotherapy	  and	  concurrent	  chemotherapy	  with	  Capecitabine	  
Weekly	  blood	  investigations	  during	  treatment:hemoglobin,total	  and	  differential	  count,platelet	  count,Serum	  creatinine,SGOT/SGPT	  and	  Alkaline	  phosphatase	  
WEEK	  0	  
WEEKS	  1-­‐6	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Figure 20: Algorithm indicating the study design 
 
 
For the study it was decided to recruit participants from the departments of Radiation 
oncology (Unit-I) and surgery (Surgery-II) from Christian Medical college, Vellore. 
A search from our departmental unit database was carried out for all patients with 
rectal cancer who had undergone 3D conformal radiotherapy. 
 
Document	  hematological	  and	  clinical	  toxicity	  based	  on	  RTOG	  CTC	  (weekly	  during	  treatment)	  
Contour	  Pelvic	  bone	  marrow	  on	  MRI	  T1	  images(on	  the	  MRI	  repeated	  prior	  to	  surgery-­‐4	  to	  6	  weeks	  following	  completion	  of	  LCCRT)	  
	  Correlate	  bone	  marrow	  dosimetric	  	  parameters(volume	  of	  bone	  receiving	  a	  particular	  dose)	  	  with	  incidence	  of	  >=grade	  3	  hematological	  toxicity(based	  on	  contouring	  of	  the	  entire	  pelvis	  on	  planning	  CT)	  	  Estimate	  extent	  of	  inactivation	  of	  bone	  marrow	  comparing	  both	  the	  pre	  RT	  MRI	  and	  the	  pre	  surgery	  MRI(based	  on	  contouring	  of	  marrow	  on	  T1	  images)	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From the above broad search, participants were recruited based on the fulfilment of 
inclusion criteria. 
Inclusion criteria 
 
• Locally advanced rectal cancer: clinical or radiological evidence of 
T3/T4 or N1 evidence; or that is and/or clinically bulky  
• No evidence of distant metastasis 
• Adenocarcinoma  
• Considered or being considered for neo adjuvant Long course 
radiotherapy (3D conformal RT) along with concurrent chemotherapy 
(concurrent Capecitabine)/or completed treatment as previously 
mentioned 
• Underwent pre and post RT MRI in our Institution  
Exclusion Criteria 
• History of prior pelvic malignancies 
• History of prior radiation to the abdomen/pelvis 
• Prior history of usage of chemotherapy/immunosuppressant 
• Known case of myelodysplastic syndrome/myelofibrosis 
• Participants with outside MRI films (either pre radiotherapy or post 
radiotherapy/pre surgery MRI) were not considered for the study (unless 
the same were repeated at our hospital). 
Sample size estimation 
The sample size for the study was determined after discussion with the statistician. 
It was determined as follows: 
Sample size for comparing toxicity rates: 
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N=(Z (1-a/2)+Z1-b))2. P1(1-P1).P2(1-P2) / (P1-P2)2 
5% level of significance Z (1-a/2)=1.96 
80%Power = Z1-b= 0.84 
D=(P1-P2)2=Difference in the toxicity rate 
 
A sample of size of 26(13 receiving less than the threshold dose and an equal number 
receiving more than the same specified threshold) was needed to detect the difference 
of 60% toxicity level between the groups with 80% power and 5% level of 
significance using an uncorrected chi-square test 
 
IRB clearance 	  
Clearance from the institutional review board and ethical committee was obtained on 
May 08,2014 
The prospective patients were recruited into the study after taking their informed 
consent (Enclosures 1-4) 
However, due to unforeseen slow accrual of patients we sought the permission of the 
IRB to modify the study design so that we could recruit retrospective patients as a part 
of the study .The same was approved by the committee on July 24,2014.  
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Work-up 	  
All patients had undergone a complete staging as well as a metastatic work up. A 
baseline CBC including Haemoglobin, total count, differential count, platelet count, 
renal and liver function tests, CEA, ECG, Echocardiograph, Chest radiograph, MRI of 
the abdomen and pelvis was obtained for all patients. Height,Weight,baseline BSA 
was calculated for all patients. Cardiology clearance was taken prior to starting 
chemotherapy. 
Other parameters that were recorded were: 
Location of the tumour (upper, middle or lower rectum) 
Proliferative or ulcerative tumour 
Presence or absence of circumferential involvement 
Presence or absence of anorectal involvement. 
 
Staging of rectal cancer was based AJCC cancer staging manual 7th edition, 2010 
  
The clinical and radiological findings of all patients were discussed in a multi 
disciplinary tumour board comprising of Radiation Oncologists, Surgical Oncologists, 
Medical Oncologists, Diagnostic and Radiologists .The consensus decision was to 
offer Neoadjuvant radiotherapy using 3D conformal radiotherapy along with 
concurrent chemotherapy with daily Capecitabine. 
All the patients in this study were proposed to receive neo adjuvant long course 
chemoradiotherapy using 3D conformal technique. 
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3D Conformal therapy 	  
Position: 
All patients were simulated and treated in the supine position. The forearms and 
hands were placed over the chest or upper abdomen, based on the patient’s preference 
Immobilization: 
An immobilization device utilizing a vacuum assisted bag the VAC-LOC was made 
for all patients. 
3 Fiducial markers were placed on the patient’s body and their positions prior to CT 
simulation were verified by aligning them using the in-room lasers. 
Planning CT protocol 
The simulation CT was acquired as follows: 
Informed consents for using oral and IV contrast were taken. 
Patients were asked to lie supine on the flat couch insert along with the vacloc and the 
positions of the patient and the fiducials were verified. 
Oral contrast was given to aid in visualization of the small bowel. 
IV cannulas were placed and their patency verified. 
The scout film was viewed to verify patient position. 
IV contrast (1ml/Kg) was injected using a machine driven piston. 
5mm cuts were acquired from the level of the diaphragm superiorly to the level of the 
mid thighs inferiorly. 
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Target delineation  
Volume delineation was carried out as follows: 
GTV: The rectal growth visualized on imaging. Clinically or radiologically involved 
nodes. 
CTV: Areas of subclinical disease extension including the entire mesorectum, 
presacral space and the internal iliac group of lymph nodes. 
PTV: Symmetric or asymmetric expansion of the CTV to account for set up and 
systematic errors. 
Phase I: The above-mentioned PTV  
Phase II: The tumour or the post operative site with a 3 cm margin. The nodal stations 
were not routinely included in the phase II volume. 
Protocol for contouring of the entire pelvis on planning CT 
The entire pelvis and parts of the lumbosacral spine and proximal femurs including 
the head and trochanters were contoured on the planning CT for all patients. 
Contouring was carried out as follows: 
 
The bone window was used. 
Entirety of the bone from L5-S1 junction or from the level of the superior most 
section including the PTV phase I, whichever was higher. The inferior extent was at 
the lowermost level of the ischial tuberosity. 
The dosimetric parameters relating the bone marrow such as V5, V10, V20, V30 and 
V40 were recorded. 
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Figure 21: Delineation of the Pelvis on the planning CT 
 
Figure 22: 3-D reconstruction of the delineated pelvis (pink) and the PTV (Red) 
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Protocol for estimating marrow inactivation 
 
The active marrow (red marrow) was contoured on the MRI abdomen and pelvis on 
the T1 weighted images along with the assistance of a senior radiologist. 
The images that were acquired were reviewed by the radiologist. The active marrow 
on both the pre radiotherapy MRI as well as the post radiotherapy MRI was contoured 
by the radiologist as follows: 
The yellow marrow has hyperintense signal intensity on T1; red marrow has a relative 
hypointense signal intensity compared to yellow marrow but a higher intensity than 
that of the muscle.   
The marrow was delineated on the axial images; the superior and inferior limits being 
the same as that used for contouring the bone on the planning CT. The summated 
volumes of the active marrow on both the pre as well as the post treatment MRI’s 
were recorded. The percentage inactivation of active marrow was also calculated. 
  
	  59	   	  
 
Figure 23: T1-w axial images of the pelvis. The hypointense areas were contoured 
indicating islands of active marrow (areas numbered 1-8). 
 
Figure 24: Hypointense areas on T1-w axial images representing islands of active red 
marrow (areas numbered 1-8;denoted by blue arrows 
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Plan evaluation 
The plans were evaluated based on ICRU principles where in the target volume 
coverage and distributions were reviewed while ensuring that the organs at risk 
received a dose that was within their tolerance limits. 
 
Figure 25: Isodose coverage of the targets as a part of plan evaluation 
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Figure 26: DVH of both the target volumes as well as the organs at risk; note the blue 
unbroken line representing the DVH of the pelvis (represented by the arrow)  
 
 
 
Treatment delivery 
All patients received treatment on the SIEMENS PRIMUS linear accelerator with a 
dose of 45Gy in 25 fractions delivered to the phase I volume followed by an 
additional 5.4Gy in 3 fractions delivered to the Phase II volume. 
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Concurrent chemotherapy 	  
All patients received concurrent chemotherapy with Capecitabine (825mg/m2) given 
Monday to Friday (on the days of receiving radiotherapy) 
The need, the benefits and side effects expected with radiotherapy and chemotherapy 
were explained to patients and their informed consents taken. 
Weekly assessment 	  
Patients underwent a weekly assessment during the course of radiotherapy. Clinical 
toxicities were documented as per the RTOG toxicity grading system. Weekly blood 
investigations including Hemoglobin, total and differential counts, platelet count, 
liver function tests and Serum creatinine were ordered. 
Patients underwent a reassessment of their disease status 6 weeks following 
completion of the Neoadjuvant treatment. Apart from the above-mentioned 
investigations, they also underwent MRI of the pelvis to assess tumour downstaging. 
Variables 
The variables that were considered were:  
1) Hematological toxicities- 
Toxicities relating to Hemoglobin, Total leucocyte count, absolute 
neutrophil count, lymphocyte count and platelet count were graded 
separately according to the Cooperative group common toxicity criteria 
(RTOG) 
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2) Bone Dosimetric parameters-	   
Such as V5, V10, V20, V30 and V40 both in terms of absolute volume 
in cc as well as the relative volume in percentage. 
 
3) Volume of active marrow- 
The volumes on the pre radiotherapy MRI, the volume of active 
marrow noted on the post radiotherapy MRI and the percentage inactivation of 
active marrow were noted. 
Sources of Data 	  
The source of data was as follows: 
 
Clinical data- Department of Radiation oncology 
 
Radiological investigations-MRI Pelvis and abdomen (Pre and Post radiotherapy-
baseline and the MRI repeated 4-6 weeks after LCCRT)-Department of 
radiodiagnosis 
 
Histopathology-Department of pathology 
 
Hematological investigations: Hemoglobin, Total count, Differential count, Platelet 
count-Department of Clinical pathology 
 
Biochemical profile: Liver function tests, Serum creatinine, Serum urea, Serum 
Electrolytes-Department of Clinical Biochemistry 
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Dose of Radiation delivered to the bone marrow-Generation and Interpretation of the 
DVH on the TPS-Departments of Radiation Physics and Radiation Oncology. 
  
 
The incidence of haematological toxicity, the grade of toxicity and its correlation with 
the bone dosimetric parameters were attempted. 
The incidence and grade of haematological toxicity and its correlation with the 
percentage inactivation of the active marrow was also carried out. 
 
 
Figure 27: RTOG toxicity criteria 
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Statistical methods 
The statistical methods were carried out as follows:  
 
The data was summarized using weekly blood counts, weekly toxicities of 
Haemoglobin, Leucopenia, Neutropenia, Lymphopenia, Thrombocytopenia, the 
lowest toxicity graded during the course of chemoradiotherapy. The absolute volumes 
as well as the percentages of the bone marrow were recorded in each of the dosimetric 
groups (V5, V10, V20, V30 and V40). 
 
The Volumes of the marrow seen on the pre radiotherapy MRI as well as on the post 
Radiotherapy MRI were recorded both in absolute volume in cc as well as in 
percentages. 
 
Univariate analysis of each of the dosimetric groups was carried out. The mean, the 
standard deviation, the median and the quartiles were tabulated. 
 
The correlation between the toxicity levels (grade 3 and more) and the bone 
dosimetric variables were compared using the Shapiro Wilk test and the Mann 
Whitney test (Two sample Wilcoxon rank sum test). 
 
A paired T-test was applied to find out the difference between the pre and the post 
chemoradiotherapy bone marrow volumes. 
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Results 
We carried out a search of our departmental unit database (Department of Radiation 
Oncology-Unit I), for patients with locally advanced rectal cancer who received 3D 
conformal radiotherapy. 
From January 2012 to August 2014,we identified 27 patients who met the above two 
criteria. On reviewing the clinical and treatment details, we found that 7 patients were 
not suitable for the study as they did not meet the eligibility criteria. The biopsies of 
the rectal growth of two of the seven patients were not reported as adenocarcinoma 
(being neuroendocrine tumour in one and melanoma in the other). 3 patients out of the 
above seven had undergone upfront surgery and received radiotherapy as adjuvant 
therapy. 
3 patients out of seven had received chemotherapy prior to initiation of radiotherapy.6 
patients had received neo adjuvant chemoradiation using 3D conformal therapy, but 
had to be excluded from the study as they did not have the post radiotherapy MRI of 
the pelvis. 
After excluding the above patients we analyzed the details of 20 patients who met the 
eligibility criteria.  
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Patient Demography 
ID NO AGE SEX MARITAL  STATUS OCCUPATION 
1 41 Female Married Skilled worker 
2 55 Male Married Skilled worker 
3 44 Male Married Skilled worker 
4 52 Female Married Skilled worker 
5 65 Male Married Skilled worker 
6 56 Male Married Skilled worker 
7 64 Female Married Skilled worker 
8 29 Male Umarried Skilled worker 
9 57 Male Married Skilled worker 
10 36 Female Married Skilled worker 
11 67 Female Married Skilled worker 
12 64 Male Married Skilled worker 
13 66 Male Married Skilled worker 
14 69 Male Married Skilled worker 
15 53 Female Married Skilled worker 
16 64 Female Married Unskilled worker 
17 41 Male Married Skilled worker 
18 57 Male Married Skilled worker 
19 53 Female Married Skilled worker 
20 19 Female Unmarried Unskilled worker 
Table 1: Demographic details 
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Table 2: Table with representation of patients less than 45 years of age 
 
We found that there were 11 male and 9 female patients with a mean age of 52 years 
(range 19-69). 30% of the patients were below the age of 45 years.18 patients were 
married and 2 were unmarried.  
  
AGE NUMBER PERCENTAGE 
<45 yrs 6 30 
>45 yrs 14 70 
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Tumour characteristics 	  
Id No Location Of Tumour Anorectal 
Involvement 
Circumferential 
Involvement 
1 Lower Yes Yes 
2 Lower  Yes Yes 
3 Upper No No 
4 Lower  No Yes 
5 Middle No Yes 
6 Middle  No Yes 
7 Upper  No Yes 
8 Middle  No No 
9 Lower  Yes No 
10 Middle  No No 
11 Lower  Yes Yes 
12 Middle  No Yes 
13 Upper  No Yes 
14 Upper  No Yes 
15 Upper  No No 
16 Lower  Yes Yes 
17 Lower  Yes Yes 
18 Upper  No Yes 
19 Upper  No No 
20 Upper  Yes Yes 
Table 3: Table with tumour characteristics 
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8 patients had upper rectal growths, 5 in the middle rectum and 7 in the lower 
rectum.7 patients had involvement of the anorectum. It was also noted that 14 patients 
had a circumferential growth. 
 
Stage characteristics 
 
T Stage 
T STAGE NUMBER PERCENTAGE 
2 0 0 
3 15 75 
4 5 25 
Table 4: T stage characteristics 
Nodal involvement 
NODAL STAGE NUMBER PERCENTAGE 
0 1 5 
1 6 30 
2 13 65 
Table 5: N stage characteristics 
Since only patients with locally advanced rectal cancer were considered, 15 patients 
had T3 disease whereas 5 patients had a T4 growth. 12 patients had an N2 status, 
while 5 had a nodal status of 1.There was only one patient who had no radiologically 
detected nodes.  No patients with metastasis were included in the study. All patients 
had a performance score of either 0 or 1.  
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Dosimetric variables 	  
 
Univariate analysis of the bone dosimetric variables were as follows: 
 
1) V5: The median value of V5 was 99.83%(959.07cc) ranging between a 
minimum and maximum values of 88.75%(631.94cc) to 99.99%(1430.63cc)   
2) V10: The median value of 97.62%(931.32cc) ranging between 
82.88%(629.97cc) to 99.99%(1403.83cc) 
3) V20: The median value of 93.91%(872.98cc) ranging between 
65.14%(615.38cc) to 98.97%(1361.69cc) 
4) V30: The median value of 66.27%(618.26cc) ranging between 50%(310.04cc) 
to 93.54%(880.21cc) 
5) V40: The median value of 45.50%(444.40cc) ranging between 
36.58%(300.74cc) to 56.25%(635.61cc) 	  
Toxicity grading 	  
Weekly blood investigations were recorded and the grading of toxicity for 
different blood elements was carried out on a weekly basis. In addition to the 
weekly grading of toxicity, the highest grade of toxicity experienced during the 
course of neo adjuvant chemoradiotherapy was also noted.	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Results were as follows:	  
	  
Figure 28: Highest toxicity of all blood elements 
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1) Hemoglobin:  
Highest	  Toxicity	  
Graded	  
Frequency	   Percentage	  
0	   8	   40	  
1	   4	   20	  
2	   5	   25	  
3	   2	   10	  
4	   1	   5	  	  
Table 5: Incidence and grading of hemoglobin toxicity	  	  
2) Leucocyte count 	  
Highest	  Toxicity	  
Graded	   Frequency	   Percentage	  
0	   11	   55	  
1	   7	   35	  
2	   2	   10	  
3	   0	   0	  
4	   0	   0	  	  Table	  6:	  Incidence	  and	  grading	  of	  leucocyte	  toxicity	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  3)  Neutrophil count     
Highest	  Toxicity	  Graded	   Frequency	   Percentage	  
0	   14	   70	  
1	   5	   25	  
2	   0	   0	  
3	   1	   5	  
4	   0	   0	  
Table 7: Incidence and grading of granulocyte toxicity 	  	  	  
     4)   Lymphocyte count 
Highest	  Toxicity	  Graded	   Frequency	   Percentage	  
0	   0	   0	  
1	   1	   5	  
2	   4	   20	  
3	   11	   55	  
4	   4	   20	  
Table 8: Incidence and grading of lymphocyte toxicity 	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5)  Platelet count 
Highest	  Toxicity	  Graded	   Frequency	   Percentage	  
0	   19	   95	  
1	   0	   0	  
2	   0	   0	  
3	   1	   5	  
4	   0	   0	  Table	  9:	  Incidence	  and	  grading	  of	  platelet	  toxicity	  	  	  	  
Grade 3 or more toxicity 
When only grade 3 or more toxicity was considered the following were noted:	  
Grade 3 or more toxicity	   Frequency	   Percentage	  
Hemoglobin	   3	   15	  
Leucocytes	   0	   0	  
Neutrophils	   1	   5	  
Lymphocytes	   15	   75	  
Platelets	   1	   5	  
Table 10: Incidence of grade 3 or more toxicity among all blood elements 
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Hemoglobin:  
 
Using the Two-sample Wilcoxon rank sum (Mann-Whitney) test it was found that 
Grade 3 or higher Hemoglobin toxicity had a significant correlation to the V30 and 
V40 values (Prob>Z=0.0229 and 0.0095;respectively) 
There was however no correlation with the V5, V10 and V20 values 
 
Leucocytes (Total WBC count) 
 
None of the patients in the study experienced grade 3 or higher toxicity. 
Two patients experienced grade 2 toxicity. 
None of the patients received any growth factor support during the course of 
neoadjuvant chemoradiotherapy 
There was, however no correlation between the incidences of grade 2 leucopenia with 
any of the dosimetric parameters studies. 
 
Granulocytes(Absolute neutrophil count)	  
 
One patient experienced grade 3 or more toxicity. No statistical analyses could be 
performed using the dosimetric analyses for this patient 
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Lymphocytes(Absolute lymphocyte count) 
 
15 patients experienced grade 3 or more toxicities. The two-sum Wilcoxon test 
revealed no significant correlation between the incidence and the values of the 
dosimetric variables. 
 
Platelets  
 
One patient experienced grade 3 or more toxicity. The variables could however, not 
be analyzed for statistical purposes.  
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Pre and post RT Volumes of bone marrow on MRI 
ID No Pre RT volume in cc 
Post RT volume in cc Percentage 
inactivation in % 
1 405.98 115.78 71.48 
2 390.48 112.47 71.19 
3 389.69 175.15 55.05 
4 309.92 167.14 46.17 
5 451.07 236.9 47.48 
6 404.58 77.9 80.74 
7 52.54 29.72 38.98 
8 208.94 60.69 70.95 
9 367.28 205.09 44.15 
10 423.87 70.38 83.39 
11 248.89 71.59 71.23 
12 246.29 135.61 44.93 
13 180.6 56.22 68.87 
14 325.15 160.07 50.77 
15 286.94 117.11 59.68 
16 317.26 115.25 63.67 
17 382.47 221.23 42.15 
18 498.58 221.41 55.59 
19 262.4 NA NA 
20 436.78 NA NA 
Table 11: Pre and post chemoradiotherapy volumes of active bone marrow as seen on 
the MRI; Percentage inactivation of active marrow. 
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As a part of the secondary objective of the study we tabulated the volumes of the 
active bone marrow as visualized on the MRI, both prior and after neo adjuvant 
chemoradiotherapy. 
 
Univariate analysis showed the following: 
 
Pre neo adjuvant chemoradiotherapy: The volume of active marrow as visualized on 
the MRI had a median value of 346.21 cc ranging between a maximum and minimum 
value of 52.54cc to 498.58cc respectively. 
 
Post neo adjuvant chemoradiotherapy: The volume of active marrow as visualized on 
the pre operative MRI had a median value of 116.44cc ranging between a maximum 
and minimum value of 29.72cc and 236.90cc respectively. 
 
Figure 29: Graphical representation of pre and post therapy active marrow volumes 
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Percentage inactivation 	  
The percentage inactivation of active marrow that occurs following completion of neo 
adjuvant chemoradiotherapy was also calculated for all patients. 
It was noted to have a median value of 57.64% ranging between 38.98% to 83.39% 
 
Figure 30: Graphical representation of the percentage inactivation of active marrow. 
 
A paired T test was applied to verify the differences noted between the pre and post 
treatment values. 
The mean of the pre treatment value was 327.25cc with a 95% CI between 272.71 – 
381.78cc 
The mean of the post treatment value was 130.53 cc with a 95% CI between 98.86 – 
162.21cc 
The result was highly significant with a p value < 0.0001 
 
Efforts were made to review the values of the active marrow contoured on the MRI as 
well as that of the whole pelvis on the CT. 
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There was no correlation between the V5 values and the volume of active marrow on 
the pre treatment MRI 
 
The V20 showed a correlation that was marginally significant with the volume of the 
active marrow on the post treatment MRI( p value=0.0464) 
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Discussion 
 Though the incidence of colorectal cancer in India is well below that of other 
developed countries, it is of particular concern to oncologists in our country in view 
of the increasing trends (1) (91). Due to the lack of screening programs in our 
country, most of the patients in our country also present with locally advanced 
disease. The benefit of pre operative chemoradiotherapy in improving local control 
has been verified by several trials (60) (63).Neo adjuvant long course 
chemoradiotherapy followed by TME is the present standard of care for patients with 
locally advanced disease.  
 Bone marrow is exquisitely sensitive to both radiotherapy and chemotherapy 
(89). The distribution of the active marrow in the adult in the region of the pelvis, 
proximal femurs and the lumbosacral spine is close to 51% (92).The additive toxicity 
of radiotherapy and chemotherapy on bone marrow and its clinical implications has 
been well recognized and appreciated in gynaecological malignancies (84). Efforts are 
being made to decrease the toxicity by adopting different radiotherapy techniques. 
Conformal radiotherapy or Intensity modulated radiotherapy offers the possibility of 
sparing bone marrow, while not compromising on the dose delivered to the target 
volume. The advantages of ‘Bone marrow sparing IMRT’ has been shown by several 
groups in the areas of anal and gynaecological malignancies (80) (93) (87)(84) (85). 
Similar studies for rectal cancer have not been commonly undertaken. The possibility 
and the advantages of a marrow sparing technique in rectal cancer would be of 
immense benefit to the patient as well as the treating Oncologist. 
 Due to the paucity of any formal assessments of bone marrow toxicity in rectal 
cancer patients, this study was undertaken. It is also a well known fact the contouring 
of the entire pelvis on the planning CT as a surrogate for delineating the active 
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marrow is a gross over estimate (82) (88).It was therefore decided to delineate the 
marrow on the T1-w images on both the pre radiotherapy as well as the post 
radiotherapy MRI’s. 
The objectives of the study were to correlate the dose received by the pelvis with the 
incidence and degree of hematological toxicity. As a part of the secondary objective, 
we sought to get an estimate of the percentage inactivation of the bone as a result of 
chemoradiotherapy, as seen on the MRI.  
We found that the incidence of grade 3 or more toxicity of hemoglobin correlated 
with V30 and V40 values. The toxicity grades of the other blood elements however 
did not show any correlation with any of the dosimetric variables. 
The conversion of active red to inactive yellow marrow as a result of the inactivation 
of the marrow that follows chemoradiotherapy along with the correlation of their 
associated variables were found to be significant. 	  	   We faced some shortcomings associated with the study. In retrospect, we 
realize that ours is a relatively small sample size and generalization of the results to 
the entire cohort of rectal cancer patients would be a premature attempt to do so. Due 
to the slow accrual and paucity of time we had to include both retrospective as well as 
a prospective group of patients. Another limitation was that we had a relatively short 
follow up of hematological toxicity. The implications of bone marrow toxicity on the 
clinical course of patients and its correlation to oncological outcomes could not be 
completed. Also, we noted that the contouring of the bone marrow on the T1-w MRI 
images is heavily observer dependent. There are no formal guidelines or protocols 
that could have helped in better objective delineation of the bone marrow.	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The toxicity on the bone marrow due to the additive insults of chemotherapy and 
radiotherapy is by no means insignificant. Some of the recent developments in 
radiotherapy planning and delivery offer the advantage of sparing or limiting the 
dose to the organs at risk, while not compromising on the dose delivered to the 
target volumes. One such technique is the use of Bone marrow sparing IMRT, 
which has shown to be of benefit in gynaecological and anal malignancies. The 
adoption of IMRT in the treatment of rectal cancer, however, is still not 
widespread. It is hoped that with the development of better functional imaging to 
aid in radiotherapy planning, the implications of bone marrow toxicity and the 
possibility of limiting the same using IMRT, will be recognized. More studies to 
correlate the grade toxicity with dose, to correlate the degree of toxicity with both 
oncological and non-oncological treatment outcomes, are needed. The need for 
prospective study groups with an adequately long follow up would be required to 
fully appreciate the possibilities, the advantages and the limitations that these 
techniques offer. 
In spite of the above limitations, it is hoped that the present study translates into a 
small step taken in that direction. 
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Conclusion 	   	  	  The	   volume	   of	   pelvic	   bone	   marrow	   receiving	   atleast	   30Gy	   or	   more	   in	  patients	  undergoing	  long	  course	  chemoradiotherapy	  for	   locally	  advanced	  rectal	  cancer	   has	   a	   significant	   impact	   on	   anemia.	   There	   was	   also	   a	   significant	  conversion	  of	  active	  to	  inactive	  bone	  marrow	  as	  detected	  on	  the	  MRI.	  	  Due	  to	  the	  significant	  myelosuppression	  associated	  with	  the	  use	  of	  both	  chemotherapy	  and	   radiotherapy	   in	   the	  management	  of	   rectal	   cancer,	   efforts	   to	  limit	   the	   toxicity	   to	   the	  bone	  marrow	  must	  be	  undertaken.	  The	  paucity	  of	  data	  relating	   to	  and	   formally	  assessing	   the	  degree	  of	  bone	  marrow	   inactivation	  as	  a	  consequence	  of	  chemoradiotherapy	  warrants	  the	  need	  for	  further	  studies	  in	  this	  direction.	   The	   use	   of	   MRI	   and	   other	   functional	   imaging	   for	   visualization	   and	  delineation	   of	   the	   bone	   marrow	   and	   its	   use	   in	   radiotherapy	   planning	   is	   now	  providing	  possibilities	  to	  further	  limit	  normal	  tissue	  toxicity.	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Enclosures 
INFORMED CONSENT  
 
Correlation of Dose to Bone Marrow with Hematological toxicity AND 
MRI based estimation of conversion of active to inactive bone marrow in Long 
course Chemoradiation for Locally advanced Rectal cancer 
 
INFORMED CONSENT 
Sl Number: 
Participant ID:        Date: 
Participant name:       Hospital Number: 
I Mr/Mrs …………………………………………………,Son/Daughter 
of…………………………………..  Hospital number ……………………………… 
have been explained in a language that I clearly  understand about the nature of the 
condition and its associated prognosis. 
The options,the benefits of the proposed line of treatment and the side effects have 
been clearly explained to me.The costs associated with treatment have also been 
mentioned. 
The aim,the methods of collection and usage of the data,the proposed end points have 
been clearly explained to me by …………………… 
I am aware that the data collected from my participation in this study,will be utilized 
for correlating and estimating  the degree of myelosuppression caused during the 
process of my treatment. 
I am aware that my participation in this study is entirely voluntary. 
I am also aware that I may,at any time of the study,seek more information regarding 
the same.I may wish to withdraw from the study at any point,after suitable 
intimation,for reasons that I may not be willing to share. 
I hereby give my  fully  informed consent  for participation in the study.My consent 
has been given under my own free will and under no undue or external coercion. 
PARTICIPANT      WITNESS 
NAME IN CAPITALS:    NAME IN CAPITALS: 
SIGNATURE:     SIGNATURE: 
THUMB IMPRESSION:    THUMB IMPRESSION: 
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PLACE:                                                                                                            
ADDRESS AND CONTACT NUMBER: 
DATE AND TIME: 
INVESTIGATOR’S NAME AND SIGNATURE                                                                
DATE: 
 
 
  
	  97	   	  
PARTICIPANT INFORMATION SHEET 
 
Correlation of Dose to Bone Marrow with Hematological toxicity AND 
MRI based estimation of conversion of active to inactive bone marrow in Long 
course Chemoradiation for Locally advanced Rectal cancer 
 
 
 Locally advanced rectal cancer continues to be a major global burden. Though 
the problem of colorectal cancer was  comparatively lower in India until now,it looks 
like there will be an increase in the number of people who will be suffering from this 
disease in the future,due to changes in diet and lifestyle. 
The treatment of locally advanced rectal cancer is one that involves 3 different 
oncology specialties;radiotherapy,chemotherapy and surgery.One of the most 
accepted lines of management is to start with radiotherapy along with chemotherapy 
(with capecitabine).The aim is to reduce the tumour size so that the surgery may be be 
more complete.Surgery is usually carried out 4-6 weeks after completion of 
radiotherapy and chemotherapy.Following completion of surgery,further 
chemotherapy is usually given to reduce the number of tumour cells that may be left 
behind. 
Bone marrow which are the regions in the body where production of blood cells 
occurs,are usually located in the lower back,the hip bone and the upper thighs. 
Both radiotherapy and chemotherapy,though meant to act on the cancer cells,have 
side effects caused due to their effects and destruction of  normal  cells.Radiotherapy 
and chemotherapy,both have effects on the bone marrow causing reduction in the 
production of the blood cells.This is reflected in the drop in the blood counts which 
will be checked every week during treatment. 
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The effects of chemotherapy on the bone marrow can be modified by changing the 
dose of the drug given.But the effect of radiotherapy causing the bone marrow 
toxicity has not been documented clearly. 
The main aim of this study is to find out how much additional damage is being caused 
by radiotherapy. We are trying to correlate the dose received by the hip bone with the 
degree of bone marrow toxicity. We will be trying to estimate how much of the bone 
marrow is being destroyed during the course of treatment(using MRI scan) 
We would like to point out that though there are no immediate benefits to the 
participants of the study.But,with the data that will be collected,it is hoped,that we 
will be able to find out a dose to the bone marrow below which the degree of bone 
marrow toxixity will be very less(compared to the benefits that may be obtained).This 
may be beneficial in future where we will try and restrict the dose to the bonemarrow 
so that more people complete the treatment that was intended. 
The proposed study involves no additional expenses to be borne by you. The cost  
asscociated with the treatment would remain the same. 
Your participation in the study is entirely voluntary and you may wish to withdraw 
from the same at any point. However in case of withdrawal,the data collected thus far 
may be used in the analysis in order to try and come to a conclusion.I assure you that 
your personal details will not be revealed at any point  in this study. 
Your participation in this study will help doctors make better decisions in the future. 
Your participation will be deeply appreciated. 
Thank you for your interest and your  valuable time 
Please feel free to contact me for any further details that you may wish to obtain 
Dr Jayant J Bhargav 
PG Registrar 
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Department of Radiotherapy 
Christian Medical  College, Vellore 
Phone number:+919626950808 
Email:jayantbhargav@gmail.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  100	   	  
PATIENT INFORMATION SHEET IN TAMIL
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DATA COLLECTION SHEET ` 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Last                                           Middle                                                First 
 NAME       	  	  	  	  Sex	  (1=male	  2=	  female)	  	  	  	  	  	  	  	  …………………………………………………………	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Marital	  Status	  (1=	  unmarried	  	  	  2=	  married)	  	  	  	  	  	  	  ……………………………………….	  	  Occupation	  	  	  (1=skilled;	  2=unskilled)………………………………………………	  	  Location	  of	  growth	  1.Upper	  2.Middle	  3	  Lower	  …………………………………………………………………………………….	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Anorectal	  involvement/Circumferential	  involevemnt	  (1=Yes	  	  	  2=No)	  	  T	  status	  (1=T1;2=T2;	  T3=3;	  T4=4)……………………………………………………………………	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N	  Status	  (1=N1;	  2=N2;	  3=	  N3)	  …………………………………………………………………………….	  	  	  	  	  	  
GENERAL	  EXAMINATION	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  	   	   	   	   	   	   	   	   	   	  
	  	  	  	  
	  	   	   	  
	  
CHRISTIAN MEDICAL COLLEGE, VELLORE 
 Correlation	  of	  Dose	  to	  Bone	  Marrow	  with	  Hematological	  toxicity	  AND	  MRI	  based	  estimation	  of	  conversion	  
of	  active	  to	  inactive	  bone	  marrow	  in	  Long	  course	  Chemo-­‐	  radiation	  for	  Locally	  advanced	  Rectal	  cancer 
 
Case Record Form – 1 
Demographic and Clinical Details 
 
 
 
 ID NO                                              Date of Birth        Hospital Number                     Recruitment date  
                             
                                        dd        mm     yyyy                                                                             dd        mm     yyyy 
 
RT No         Telephone No             Email] 
 
    
                                           
rt no          yy      unit    
	  106	   	  
ECOG	  Performance	  status	  ………………………………………………………………………………..	  	  	  0	  =Fully	  active,	  able	  to	  carry	  on	  all	  pre-­‐disease	  performance	  without	  restriction	  	  1	  =	  Restricted	  in	  physically	  strenuous	  activity	  but	  ambulatory	  and	  able	  to	  carry	  out	  work	  of	  a	  light	  or	  sedentary	  nature,	  e.g.,	  light	  house	  work,	  office	  work	  2=	  Ambulatory	  and	  capable	  of	  all	  selfcare	  but	  unable	  to	  carry	  out	  any	  work	  activities.	  Up	  and	  about	  more	  than	  50%	  of	  waking	  hours	  3=	  Capable	  of	  only	  limited	  selfcare,	  confined	  to	  bed	  or	  chair	  more	  than	  50%	  of	  waking	  hours	  4=	  completely	  disabled.	  Cannot	  carry	  on	  any	  selfcare.	  Totally	  confined	  to	  bed	  or	  chair	  5=	  Dead	  	  	  	  	  	  	  Height	  (	  in	  cm)	  ………………………………………………………………………………………	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Weight	  (	  in	  Kg)	  ………………………………………	  ……………………………………………..	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  BODY	  SURFACE	  AREA	  (per	  square	  metre)……………………………………………………………	  	  	  	  PULSE	  RATE…………………………..	  BLOOD	  PRESSURE……………………………………	  	  	  
Systemic	  Examination:	  
	  
	  
Cardiovascular:	  
	  
	  
Respiratory:	  
	  
	  
Gastrointestinal:	  
	  
	  
Neurological:	  
	  
	  
Digital	  Rectal	  Examination	  
	  
	  
Proctosigmoidoscopy	  
	  
	  
Colonoscopy	  
	  
	  
	  
	  
	   HEMOGLOBIN	  TC	   ANC	   LYMPHOCYTES	  PLATELET	  
COUNT	  
TOXICITY	  
WEEK	  0	   	   	   	   	   	   	  
WEEK	  1	   	   	   	   	   	   	  
WEEK	  2	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WEEK	  3	   	   	   	   	   	   	  
WEEK	  4	   	   	   	   	   	   	  
WEEK	  5	   	   	   	   	   	   	  
WEEK	  6	   	   	   	   	   	   	  
	  
HIGHEST	  TOXICITY	  GRADED:	  
	  
TREATMENT	  BREAKS	  DURING	  RT:	  (1=Yes	  	  	  	  2=No)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
DURATION:	  	  	  	  	  	  	  	  	  	  
	  
REASON:	  
	  
BREAKS	  WITH	  CONCURRENT	  CHEMOTHERAPY:	  (1=Yes	  	  	  	  2=No)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
DURATION:	  	  	  	  	  	  	  	  
	  
REASON:	  
	  
	   V5	   V10	   V20	   V30	   V40	  
VOLUME	   OF	  
MARROW	  
	   	   	   	   	  
	  
VOLUME	   OF	   MARROW	   PRIOR	   TO	   NEO	   ADJUVANT	  
CHEMORADIOTHERAPY:	  
	  
	  
VOLUME	   OF	   MARROW	   POST	   NEO	   ADJUVANT	  
CHEMORADIOTHERAPY:	  
	  
	  
PERCENTAGE	  INACTIVATION:	  
	  
	  
	  	  	  	  
 
 
 
 
 
	  
	  	  
	  
	  
	  
	  
	  
Date:	  __/___/_____	  	   	   	   Investigator’s	  Signature:____________________________	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